De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)
Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…
Danielle PillsburyAugust 28, 2026
The five drug development questions that bring sponsors to pharmacometrics
Sponsors rarely come to pharmacometrics because they need a model. They come with a development…
Rik de GreefAugust 24, 2026
MBMA data curation: How AI and expert meta-analysts get it right, fast
In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…
Matt Zierhut, PhD MBAAugust 14, 2026
A model-informed approach to radioligand therapy dosing under Project Optimus
Explore how targeted radionuclide therapy dosing uses QSP, biologically effective dose (BED), and exposure-response modeling…
Hunter Stephens, PhDAugust 13, 2026
Managing drug-drug interaction (DDI) risk for patients in clinical trials
Discover how DIDB® helps clinical teams assess drug-drug interaction risk, develop prohibited medication lists, &…
Katie Owens, PhDAugust 12, 2026
Tailwinds for MIDD: What to Know About the Changing Regulatory Landscape
September 30, 2026 - 11:30 PM – 2:00 PM
CertaraAugust 12, 2026
Advances and Challenges in Model-Informed Precision Dosing of Antimicrobials for Pediatric Patients
Explore advances in model-informed precision dosing (MIPD) for pediatric antimicrobial therapy, including population PK modeling,…
CertaraJuly 29, 2026
